Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00734200 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 30 mg QD | EXPERIMENTAL | - |
| 20 mg QD | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| PF-00734200 10 mg QD | EXPERIMENTAL | - |
| PF-00734200 20 mg QD | EXPERIMENTAL | - |
| PF-00734200 5 mg QD | EXPERIMENTAL | - |
| PF-00734200 2 mg QD | EXPERIMENTAL | - |
| PF-00734200 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-00734200 30 mg QD | DRUG | 30 mg QD |
| PF-00734200 20 mg QD | DRUG | 20 mg QD |
| Placebo | DRUG | Placebo |
| PF-00734200 10 mg QD | DRUG | 10 mg QD |
| PF-00734200 5 mg QD | DRUG | 5 mg QD |
| PF-00734200 2 mg QD | DRUG | 2 mg QD |
| PF-00734200 | DRUG | The drug is administered as a single dose of four 5-mg tablets |
Inclusion Criteria: Men or women between 18-80 years of age with poorly controlled Type 2 diabetes Exclusion Criteria: Type 1 or secondary forms of diabetes Currently using insulin
PF-00734200 is an investigational small molecule being developed for type 2 diabetes mellitus and chronic renal insufficiency. It has been studied in patients with type 2 diabetes who are also taking metformin, and in subjects with impaired kidney function. The drug is not approved and remains in clinical development.
PF-00734200 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer has sponsored clinical trials of this investigational drug in the United States and several other countries.
PF-00734200 is in Phase 2 clinical development for type 2 diabetes mellitus. It has completed two Phase 2 trials and one Phase 1 trial. The drug is investigational and has not been approved by regulatory authorities.
PF-00734200 has been studied in three completed clinical trials. NCT00473525 was a 12-week Phase 2 study in type 2 diabetes patients on metformin with 303 participants. NCT00596518 was a Phase 1 study in 30 subjects with impaired or normal kidney function. NCT00618007 was a Phase 2 study in 289 type 2 diabetes patients.
PF-00734200 is the code name used by Pfizer for this investigational compound. No alternative brand names or chemical names have been publicly associated with this drug in the clinical trial records. It is identified solely by its PF-00734200 designation.